17 March 2021
At the meeting of 16 February 2021 the RMA:
Determined Statements of Principles (SOPs) for:
Condition | SOPs | |
---|---|---|
asthma | 31/2021 | 32/2021 |
acute lymphoblastic leukaemia/lymphoblastic lymphoma | 33/2021 | 34/2021 |
deep vein thrombosis | 35/2021 | 36/2021 |
pulmonary thromboembolism | 37/2021 | 38/2021 |
Note:
- The investigation concerning 'acute lymphoblastic leukaemia' has resulted in the determination of Statements of Principles concerning acute lymphoblastic leukaemia/lymphoblastic lymphoma.
The above SOPs take effect from 5 April 2021.
Summary of Changes
Decided to Undertake Consultation regarding:
Condition | Reasons for Decision | Date for Final Decision |
---|---|---|
porphyria cutanea tarda | Intention to remove one or more factors | May 2021 |
malignant neoplasm of the oral cavity, oropharynx and hypopharynx | Intention to remove one or more factors | May 2021 |
pes planus | Intention to remove one or more factors | May 2021 |
IgA nephropathy | Intention to remove one or more factors | May 2021 |
Completed Investigations
The above determinations conclude the previously advertised investigations into:
New Investigations
Decided to advertise the following investigations:
- chronic fatigue syndrome
- diabetes mellitus (focussed review - infection with Coxsackie B virus)
- malignant neoplasm of the breast (focussed review - combined hormonal contraceptives)
- steatohepatitis
- sick sinus syndrome
- morbid obesity
- malignant neoplasm of the pancreas
- heart block
- fibromyalgia
- seizure (epileptic seizure)
- epilepsy
- dermatomyositis
- dental pulp and periapical disease
- chronic solvent-induced neurocognitive disorder
- non-Hodgkin lymphoma (focussed review - infection with Epstein-Barr virus)
The above investigation notices appear in the Government Notices Gazette of 9 March 2021.